Table 1.

Patient’s characteristics and AKAP3 status. Stage grouping are based on American Joint Committee on Cancer (AJCC), Estrogen receptor (ER), progesterone receptor (PR), Her2/neu are based on IHC results. Cut point of positivity is based on American Society of Clinical Oncology (ASCO) guideline for IHC

Number of patients	74
Age (median/range) — year	48 (29–87)	Valid percent
Follow-up (median/range)—month	1 8 (1–38)
ER status (2 missing, n = 74)
Negative	40	55
Positive	32	45
PR (2 missing, n = 74)
Negative	47	65
Positive	25	35
Her2/neu status (2 missing, n = 74)
Negative	50	69
Positive	22	31
Grade (7 missing, n = 74)
G1	6	9
G2	34	51
G3	27	40
Patient status (3 missing, n = 74)
healthy survival	50	70
with events	21	30
Stage (5 missing, n = 74)
I	7	10
II	33	48
III	21	30
IV	8	12
Tumor Size (6 missing, n = 74)
<=2	24	35
>2	44	65
AKAP3 Tumor (n = 74)
Negative	47	64
Positive	27	36
AKAP3 Normal adjacent (n = 73)
Negative	40	56
Positive	32	44
Akap3 Normal Breast (n = 15)
Negative	8	54
Positive	7	46